Jazz Pharmaceuticals PLC $JAZZ Shares Purchased by Capital World Investors

Capital World Investors increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 0.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,554,867 shares of the specialty pharmaceutical company’s stock after buying an additional 10,345 shares during the quarter. Capital World Investors’ holdings in Jazz Pharmaceuticals were worth $336,731,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in JAZZ. Bank of Montreal Can boosted its position in shares of Jazz Pharmaceuticals by 2.6% in the third quarter. Bank of Montreal Can now owns 337,162 shares of the specialty pharmaceutical company’s stock worth $44,438,000 after acquiring an additional 8,687 shares during the last quarter. Swiss National Bank grew its holdings in Jazz Pharmaceuticals by 1.1% in the third quarter. Swiss National Bank now owns 111,400 shares of the specialty pharmaceutical company’s stock valued at $14,683,000 after purchasing an additional 1,200 shares during the period. Pinnacle Associates Ltd. increased its position in Jazz Pharmaceuticals by 2.9% during the third quarter. Pinnacle Associates Ltd. now owns 11,120 shares of the specialty pharmaceutical company’s stock worth $1,466,000 after purchasing an additional 312 shares during the last quarter. Natixis Advisors LLC raised its stake in Jazz Pharmaceuticals by 25.2% during the third quarter. Natixis Advisors LLC now owns 26,549 shares of the specialty pharmaceutical company’s stock worth $3,499,000 after purchasing an additional 5,342 shares during the period. Finally, Blair William & Co. IL raised its stake in Jazz Pharmaceuticals by 5.0% during the third quarter. Blair William & Co. IL now owns 2,107 shares of the specialty pharmaceutical company’s stock worth $278,000 after purchasing an additional 101 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on JAZZ. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a research note on Monday, December 29th. Truist Financial increased their target price on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Barclays reissued an “overweight” rating and set a $224.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday. Piper Sandler restated an “overweight” rating and set a $219.00 price target (up from $147.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, December 10th. Finally, Royal Bank Of Canada raised their price objective on Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $214.38.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ stock opened at $185.43 on Thursday. The company has a current ratio of 1.86, a quick ratio of 1.67 and a debt-to-equity ratio of 1.00. The company has a market cap of $11.42 billion, a PE ratio of -31.06, a P/E/G ratio of 0.34 and a beta of 0.22. The company’s fifty day simple moving average is $172.02 and its 200-day simple moving average is $155.43. Jazz Pharmaceuticals PLC has a 52 week low of $95.49 and a 52 week high of $198.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Tuesday, February 24th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping analysts’ consensus estimates of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The firm had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.17 billion. During the same period in the prior year, the company earned $6.51 EPS. The firm’s revenue was up 8.1% on a year-over-year basis. As a group, equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,287 shares of the company’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the transaction, the chief accounting officer owned 6,512 shares in the company, valued at $1,191,305.28. This represents a 16.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Norbert G. Riedel sold 3,415 shares of the stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $192.00, for a total transaction of $655,680.00. Following the completion of the sale, the director directly owned 7,024 shares of the company’s stock, valued at $1,348,608. This trade represents a 32.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 68,015 shares of company stock worth $13,037,486 in the last ninety days. 4.30% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.